The Swiss pharmaceutical giant Roche said on Monday that it would acquire a majority stake in the tumor-testing company Foundation Medicine for more than $1 billion, in a deal aimed at improving both cancer treatment and drug development.
Foundation is the leader in the growing area of sequencing the genes of tumor samples, looking for mutations that can help predict which drug will be most effective for a particular patient.
{iframe}http://dealbook.nytimes.com/2015/01/12/roche-to-buy-majority-stake-in-foundation-medicine-leader-in-tumor-testing/?_r=0{/iframe}